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S_qy Overall, the causative APC mutation has been identified in only 30% of the patients with familial
adenomatous polyposis (FAP) who have been included in studies reported the literature. In order to
determine the true frequency of detectable APC mutations, we set out to search exhaustively the entire coding
region of APC for causative mutations in ten patients with classical FAP from Scottish kindreds shown to be
linked to 5q markers. Chemical cleavage ofmismatcanalysis was employed as the initial screning technique.
Mutations were confirmed by direct DNA sequencing and shown to generate a premature stop codon by an in
vitro protein synthesis assay. Mutations resulting in a premature stop codon either by base substitution or by
frameshift were identied in nine families. Although the remaining kindred was linked to intragenic APC
markers with a lodscore of 1.69 at Z,,, = 0.0, further analysis of DNA, RNA and chromosome spreads from
the proband failed to detect any abnormality. This was despite employing single-strand conformation
polymorphism (SSCP) analysis, heteroduplex analysis, DNA sequencing, revese transription-polymrase
chain reaction (RT-PCR) analysis for splicing defects, a protein truncation test encompassing the entire APC
gene and fluorescent in situ hybridisation chromosome analysis (FISH). These data show that 90% of these
FAP kindreds had APC mutations detectable by chemicl cleavage of mismatch and that none of the
numerous other techniques employed could detect the mutation in the remaining kindred. This study shows
the value of screening the APC gene using a combination of chemical cleavage of mismatch analysis and an in
vitro protein truncation test.
Familial adenomatous polyposis (FAP) is an autosomal
dominant heritable disorder with a population frequency of
around 1:7,000. Penetrance is almost 100% and the syn-
drome is characterised by the development of hundreds or
thousands of colorectal polyps during the second decade of
life. The presence of more than 100 adenomatous polyps is
diagnostic of FAP. Progression of one or more of the polyps
to carcinoma is almost inevitable unless prophylactic surgical
excision of the large bowel is performed (Murday et al.,
1989). The clinical manifestations of FAP are a result of
mutations in APC, a gene located on chromosome 5q21-q22
and for which the entire coding sequence is now known
(Groden et al., 1991; Kinzler et al., 1991; Nishishio et al.,
1991). Nonethekss, of over 800 FAP patients reported in the
world literature, the overall frequency of identifying the
causative mutation is only 30% (Nagase et al., 1992a; Nagase
& Nakamura, 1993; Mandl et al., 1994) and ranges from
21% (Mandl et al., 1994) to 67% (Nagase et al., 1992a). This
may reflect any one or more of the following: the selection
criteria for the diagnosis of FAP, the sensitivity and robust-
ness of the mutation detection technique employed, the
assiduousness of the search for mutations, the presence of
causative gene alterations influencing APC expression out-
with the coding sequence and the possibility of genetic
heterogeneity in FAP.
Presymptomatic colonic screening of at-risk relatives and
appropriate prophylactic surgery considerably reduces mor-
bidity and mortality from FAP (Jarvinen, 1992). Since
reliable diagnosis by identification of constitutional muta-
tions in the APC gene will obviate the need for frequent
colonoscopy of relatives at risk, it is of substantial clinical
importance to know what proportion of patients carry cons-
titutional APC alterations and with what reliance these can
be detected. With this in mind, we undertook an exhaustive
examination of the APC gene in a group of ten unrelated
FAP patients who had both a secure clinical diagnosis of
FAP and who were from kindreds in which there was
evidence of genetic linkage to APC markers. Mutation detec-
tion in this study was exhaustive, employing chemical
cleavage of mismatch analysis (HOT, for hydroxylamine and
osmium tetroxide used in the technique) as the primary
screening procedure. In the patient in whom no variant was
found by HOT analysis, we performed further, extensive
studies in an attempt to identify the underlying APC muta-
tion, including SSCP, heteroduplex analysis, DNA sequenc-
ing, RT-PCR analysis for splicing defects, fluorescent in situ
hybridisation (FISH) chromosome analysis and a
modification of a protein truncation assay (PIT) (Powell et
al., 1993; Roest et al., 1993) using a coupled transcrip-
tion-translation system.
Materia a and -hod
Ten patients with FAP (i.e. > 100 adenomatous polyps noted
in the colonic resection specimen) from families which had
previously shown some evidence of genetic linkage to 5q
markers were selected at random from Scottish families col-
lected as part of a national registry. DNA samples and/or
lymphoblastoid cell lines for RNA studies were obtained.
DNA and RNA purification was performed to standard
protocols. The clinical phenotype and particular mutation
found are detailed for each subject in Table I. The measure
of density of polyps was divided into dense and sparse on
subjective assessment of clinical photographs or clinical
inspection of the colon without a numerical definition since
such a definition would be dependent on the assiduousness of
the search for polyps.
DNA sequencing
PCR fragments shown to contain a variant band on muta-
tion screening by HOT analysis was reamplified with the
same primers and double-stranded sequencing performed as
described (Winship, 1989) using either the forward or the
reverse primer to detect the causative APC mutation.
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HOT anal}sis
The HOT technique. which detects in the region of 100% of
mutations. was used on DNA fragments PCR amplified from
blood lymphocyte DNA as previously descnrbed (Cotton et
al.. 1988: Condie et al.. 1993). The gene was amplified exon
by exon according to published primers (Groden et al.. 1991).
Fourteen overlapping fragments covered exons 1-14 and
varied in size from 173 to 458 bp. In exon 15 the size of the
amplified fragments was doubled, resulting in 11 instead of
23 fragments. ranging in size from 542 to 870 bp. Twenty-five
PCR amplified fragments covered the entire gene from 20 bp
5' of the initiating ATG to 31 bp 3' of translation termina-
tion. The 5' primer of exon 3 was entirely within exon 3 and
of exon 4 extended into exon 4. Mutations under these
primers would not be detected. nor would splicing mutations
involving the donor sites of introns 2 and 3. but these regions
constitute a very small proportion of the entire gene.
Single-stranded conformational poly morphism (SSCP)
anal! sis
PCR amplification of all APC fragments was carried out as
described by Groden et al. (1991). incorporating 0.25 JACi of
[3'2PCTP for each reaction. SSCP was carried out as
previously described (Orita et al.. 1989; Groden et al.. 1991).
PCR products were denatured and run on 6% polyacryl-
amide gels with 10% glycerol at room temperature under
non-denaturing conditions. Gels were dried and autoradio-
graphv performed for 6-24 h.
Heteroduplex analysis
PCR amplification of all APC fragments was camred out as
described for SSCP analysis and heteroduplex analysis per-
formed as described (Nagamine et al.. 1989). Autoradio-
graphs were assessed after 6-24 h).
Protein truncation test (PTT)
PCR amplification was used to introduce the 17 bp consensus
T7 promoter sequence and a mammalian translation initia-
tion sequence in-frame with unique APC sequence as
previously described (Powell et al.. 1993). Unique primers for
most of exon 15 were as described by Powell et al. (segments
3-5). but we modified primers for exons 1-14 in order to
analyse cDNA templates for exons 1- 14 in two overlapping
reactions. We also designed the forward primer for the most
5' part of exon 15 to be closer to the splice site. Therefore. a
total of six forward primer sets were designed in the follow-
ing way: T7 consensus promoter sequence-spacer-Kozak
consensus sequence-ATG-unique APC sequence in-frame
with the ATG in order to allow overlapping fragments of the
entire gene when suitable reverse primers from the published
sequences (Groden et al.. 1991) were selected.
Exons 1- 14 were amplified from cDNA which had been
reverse transcribed from lyphoblastoid cell line RNA using a
two-stage nested PCR technique with the internal primer
bearing the T7 promoter and initiation sequences. Primer
sequences used in the PTT are shown in Table II. PCR
products were then used without purification in a coupled
transcription-translation reaction (Promega UK) incor-
porating 40 gCi of [35Slmethionine according to the manufac-
turer's instructions. The resultant products were diluted in
buffer. boiled and analysed by 8%, 10% and 12%
SDS-PAGE gels. Gels were washed in fix and autoradio-
graphy performed at room temperature overnight.
Fluorescent in situ hvbridisation (FISH1
Biotinvlated cosmids were hvbridised to metaphase slides
from short-term peripheral blood cultures from the patient
and hybridised probe was detected by alternate layers of
aviidin-FITC. biotinylated anti-avidin and avidin-FITC as
previously described (Fantes et al.. 1992). Twenty metaphases
were examined for each probe for the presence of signal on
both chromosomes 5 using a BioRad laser scanning confocal
microscope.
Results
Using HOT analysis-and sequencing of variants. we found
inactivating constitutional mutations in nine patients (90%).
Mutations were found in exons 4. 6 (three). 8. 13 and 15
(three) Table I and Figure 1). Three mutations constituted
deletions (of 1 bp. 2 bp and 4 bp) leading to subsequent stop
codons by frameshift. Six mutations were C-T transitions at
CpG sites. in each case changing an arginine to a stop.
One-third of the mutations were found in exon 15. although
none was found in mutational hotspot regions of the gene
(A1061 and A1309 in exon 15) (Nagase & Nakamura. 1993).
No double mutations were detected despite analysis of the
entire APC gene in every patient.
We were unable to detect any alteration in the APC gene
in one FAP patient (MD129). The kindred of this patient
was relatively small and DNA was not retrievable from some
deceased family members. However, linkage analysis using
intragenic APC polymorphisms achieved a peak lod score of
1.69 at 0 = 0.0, thereby substantially excluding the possibility
of another non-Sq-linked locus being involved. HOT analysis
had shown no heterozygosity at any of the known APC
polymorphic sites even though more than 20 intragenic
restriction site polymorphisms (summarised by Nagase et al..
1992h) were screened. In addition. flanking linked markers
EF544 and L562 (Dunlop et al.. 1990) showed no
heterozygosity and a 3' PCR-amplifiable SspI polymorphism
(Heighway et al.. 1991) was found to be homozygous. SSCP
and heteroduplex analysis of each segment of APC in patient
MD129 also failed to reveal any mutation or polymorphisms.
In view of the persisent evidence of homozygosity at every
locus examined. we considered whether the patient might be
hemizygous at the APC locus. Karyotype analysis of G-
banded chromosome spreads from peripheral lymphocytes
identified two normal chromosome 5 homologues. Therefore.
fluorescent in situ hybridisation (FISH) was carried out using
cosmids that map to the APC locus (ym75 maps within the
Table I Mutation and clinical features for each patient
Age at Polip Extracolonic
Patient diagnosis density features Mutation Exon
MD]15 18 Dense None Del A at nt3578 15
MD122 18 Dense Epidermoid cysts CGA->TGA at nt904 8
MD129 23 Dense None Not found N A
MD148 27 Dense Epidermnoid cysts CGA->at nt694 6
MD033 18 Dense None CGA->at nt2626 15
MD158 35 Sparse Epidermoid cysts DelATAG at nt509 512 4
MD166 39 Dense None CGA->TGA at nt1660 13
MD212 45 Sparse Osteomas CGA->TGA at nt646 6
MD245 18 Dense Osteomas CGA->TGA at nt646 6
Cholangiocarcinoma
MD250 25 Dense Osteomas, desmoids DeLAG at nt4388 4389 15PROTEIN TRU,NCATION AND HOT ANALYSIS IN FAP 843
Table II Primer sequences for the protein truncation test
Reverse
RT-PCR external pnrmers (exons 1- 15)
5'-CAAGGGTAGCCAAGGATGGC
Exon I -II RT-PCR internal primers
5'-T7 promoter + Kozak + ATG GCTGCAGCTTCATATGATC-3'
Exon 9-15 RT-PCR internal primers
5'-T7 promoter + Kozak + ATG CGACAGTCTGGATGTC-3'
Exon 15 codons 686-1.283
5'-T7 promoter + Kozak + ATG GAGAACAACTGTCTACAAACT-3'
Exon 15 codons 1.099-1.701






Exon 15 codons 1.547-2.256
5'-T7 promoter + Kozak + ATG GAAAACCAAGAGAAAGAGGCAG-3' 15P2
Exon 15 codons 2.131-2.843
5'-T7 promoter + Kozak + ATG GGTTTATCTAGACAAGCTTCG-3' 15U2
All primer identification (e.g. 15J2) corresponds to sequences published by Groden et al. (1991). and when
new primers were designed the sequence is given in full. For the protein truncation test the consensus T7 promoter.
spacer. Kozak initiation sequence and methionine was as described by Roest et al. (1993).
5'-GGATCCTAATACGACTCACTATAGGAACAGACCACCATG-3'. and is referred to for each primer as T7






































Figure 1 Sequence of each of the nine mutations found. In each case the mutant and wild-type sequence can be seen as
double-stranded DNA was sequenced directly from PCR amplification products as described (Winship. 1989).
APC gene while vm72 maps to the 3' untranslated region;
Hampton et al.. 1992). There was no evidence of
hemizygosity, each chromosome 5 showing hybridisation to
the labelled probe. Representative results for ym75 are shown
in Figure 2.
We next looked for evidence of a splicing defect within the
APC transcript by a RT-PCR experiment of the first 14
exons. mRNA was prepared from a lymphoblastoid cell line
from patient MD129, reverse transcribed and the cDNA
templates amplified using a coding sequence primer from
exon I and a reverse primer from exon 15. Once again. no
abnormality was noted (data not shown).
In order to screen the entire gene for truncating mutations
which might have been missed by DNA analysis. we carried
out a protein truncation test, first described by Roest et al.
(1993) and applied to APC screening by Powell et al. (1993).
This involves a PCR-based generation of APC surrogate
transcripts which are used in a coupled transcrip-
tion-translation reaction for in vitro APC protein synthesis.
Translation products are then assessed for evidence of trun-
cation by standard SDS-PAGE. Patients found to have
mutations by HOT analysis were used as positive controls.
All of the patients with a mutation in exon 15 and patient
MD212 for exon 6 were used as appropnrate positive controls
and exhibited a truncated protein. No truncated protein
product was detected for patient MD129 in any of the over-
lapping PCR fragments although the full-length wild type
APC was seen clearly for each fragment analysed (Figure 3a
and b).
Finally, we sequenced the first three exons of APC and
intron-exon boundaries (excluding the sequences 5' of exon
1 as this was not fully characterised) because the very small
PCR fragments and resultant protein products generated by
the PT-T could have been degraded or lost during analysis.
However, no sequence variations were noted from published
sequence or from our control DNAs.
We have studied ten kindreds with a secure clinical and
pathological diagnosis of FAP. each of which was known to
be linked to chromosome 5q21. The causative mutation was
detected in nine of these families, but despite extensive study
Foriiard54 J. PROSSER et al.
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Fe 2 FISH chromosome analysis of spreads from patient
MD129. Hybridisation to both chromosome 5 homologues can
be seen clearly.
we were unable to identify the mutation in the remaining
patient. The peak lod score of 1.69 with no recombinants in
the family strongly suggests that dysfunction of APC is the
undelying moleular lesion in this kindred. However, our
studis indicate that there is no mutation in the coding
sequence and APC splicing is normal.
In the published literature, there is little evidence of
clustering of APC mutations with only a few mutations (4 or
5 bp deletions at codons 1,061 and 1,309) being at all com-
mon, and together accounting for around 10% of all pub-
lished mutations. Furthermore, since the reported mutations
in the APC gene are scattered across the gene (Nagase &
Nakamura 1993), it is apparent that the entire coding region
will require screening in a proportion of patients. The two
main screening techniques used here, namely HOT analysis
and PFT, are complementary. We initially set out to screen
APC using the HOT technique, an extremely eff&ient method
ofmutation detection. However, we now feel that a combina-
tion of analysis by FTT with follow-up by HOT is optimal.
The FIT technique applied here is ideal to screen 1-2 kb of
cDNA or a single large exon of genomic DNA since essen-
tially all causative APC mutations result in premature stop
codons. The entire gene can be screened in just six overlapp-
ing PCR reactions from cDNA templates. The demonstration
of truncation of in vitro synthesised APC product is defacto
evidence that the mutation is due to a premature stop codon.
Since all confirmed published APC mutations resulting in
FAP are due to truncating mutations, the technique provides
immediate confirmation that the mutation is causal in any
patient analysed. However, because it is not possible to
overlap the fragment analysed at the most 5' end of APC,
HOT analysis or sequencing of the first three exons is
required if no mutation is found elsewhere since very short
protein fragments are easily lost by degradation or during
SDS-PAGE. PIT is particularly valuable once a number of
positive controls have been identified and the mutation is
localised within the gene. Such 'marker' mutations help to
localise newly discovered variants for further HOT analysis
and final identification by DNA sequencing.
While FTT provides evidence of a truncating mutation, it
does not localise the underlying mutation particularly well.
The complementary accurate localisation afforded by HOT
analysis allows precise targeting of subsequent DNA sequen-
cing. HOT analysis is particularly valuable when double-
stranded DNA sequencing is somewhat ambiguous. While
the HOT technique is very sensitive, detecting in the order of
Fu1ue 3 Example FIT analysis from two separate APC
fragments in exon 15. a, FIT of codons 686-1,283. MD129 (no
tnmcated protein), MD115 (delA at nt 3,578) and MD033 (C-T
substitution at nt 2,626) in lanes 1, 2 and 3 r y. b, PFI
ofcodons 1,099-1,701. Lanes 1 and 2 normal control DNA with
60kDa wild-type product, lanes 3 and 4 control FAP patient
DNA with known stop codons outside the fragment under
analysis showing 60kDa product. Lane 5, patient MD129 (no
truncated protein); lane 6, positive control MD250 (de1AG at nt
4,388/4,389) with 36kDa APC product.
100% of mutations (Condie et al., 1993), it is also labour
intensive when employed to analyse a gene such as APC at
the DNA level. Although it may be an unattractive technique
to screen substantial numbers of FAP patients, it is partic-
ularly useful for back-up screening when other methods of
mutation detection, such as SSCP and heteroduplex analysis
have failed. This would best be done by analysis of 1 kb
cDNA templates generated by RT-PCR. It is desirable to
characterise the mutation by DNA sequencing, as this may
then allow use of a simple restriction digest for predictive
testing of at-risk individuals in whom the mutation alters a
restriction site.
It has been suggested that mutations occurring towards the
5' part ofthe gene have an attenuated phenotype, while those
at the 3' end are more severe (Nagase et al., 1992b; Groden
et al., 1993; Spiro et al., 1993). While our primary aim was to
assess and develop an APC mutation screning strategy in a
relatively small number of patients, the data presented here
support the apparent association of attenuated phenotype
FAP with mutations in exons 3 and 4 (Spiro et al., 1993).
Patient MD158 with a mutation in exon 4 had around one
hundred polyps at diagnosis at the age of 35 years and wouldPROTEIN TRUNCATION AND HOT ANALYSIS IN FAP 845
be appropriately allocated to an attenuated phenotype group.
In contrast, patient MD245 with a mutation in exon 6, only
a few hundred base pairs from the MD158 mutation,
developed numerous symptomatic polyps at 18 years of age
and died of cholangiocarcinoma at the age of 26 years.
Hence, these data support the notion of a relatively sharp
delineation of regions within the gene (Olschwang et al..
1993; Spiro et al., 1993) which, when inactivated by muta-
tion, result in quite different phenotype. Interestingly, small
peripheral CHRPE lesions were present in the patient
MD158 and three other affected family members, which is at
odds with a recent report showing that almost all patients
with mutations proximal to exon 9 have no CHRPE lesions
(Olschwang et al., 1993). Of the other three patients who had
a mutation proximal to exon 9 (MD122, 148 and 212) and
who underwent eye examinations, no CHRPE lesions were
found.
Patients MD212 and MD245 had identical mutations
(substitution of T for C at nt646) but we could not find any
evidence of common ancestry, despite investigation of four
generations in each family in the Scottish Register House.
However, the families were from the same geographical
region of Scotland and it is certainly possible that there is a
founder effect.
This report has described an exhaustive approach to muta-
tion detection in APC in 5q linked FAP patients with a
secure clinical diagnosis using the most sensitive screening
technique available, namely HOT analysis. We have emp-
loyed an APC protein truncation assay to good effect, and
this technique holds much promise for future screening of
FAP families. Although we have been able to characterise the
causative mutation in the highest proportion of patients
analysed in any published series, we have been unable to
detect the causative mutation in patient MD129. There is a
possibility that this family represent a FAP phenocopy but
we consider this highly unlikely since all clinical and
pathological data point to a diagnosis of polyposis coli and
genetic linkage analysis strongly supports the involvement of
APC. The most likely explanation of our findings is that
there may be a promoter mutation influencing expression of
APC. It will be of interest to screen the APC promoter in
this patient once this region is fully characterised.
Abbreriatioo: CHRPE, congenital hypertrophy of the retinal
pigmentation epithelium; FISH, Fluorescent in situ hybridisation;
HOT, hyroxylamine osmium tetroxide; nt, nucleotide; PTm, protein
truncation test; RT-PCR, reverse transcription with polymerase
chain reaction; SSCP, single stranded conformational polymorphism.
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